Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Translational Metabolism
Published in: Clinical Reviews in Bone and Mineral Metabolism 3/2018

01-09-2018

Bringing Attention to Lesser-known Bone Remodeling Pathways

Authors: Mehdi Shadmand, Krista Jackson, Cecelia Bender, Stephen Donnelly, Henry Guan, Kirby Tobin, Sydni Yates, Julia Hum, Jonathan W. Lowery

Published in: Clinical & Translational Metabolism | Issue 3/2018

Login to get access

Abstract

Osteoporosis, a disease of low bone mass, places individuals at enhanced risk for fracture, disability, and death. In the USA, hospitalizations for osteoporotic fractures exceed those for heart attack, stroke, and breast cancer and, by 2025, the number of fractures due to osteoporosis is expected to rise to nearly three million in the USA alone. Pharmacological treatments for osteoporosis are aimed at stabilizing or increasing bone mass. However, there are significant drawbacks to current pharmacological options, particularly for long-term management of this chronic condition. Moreover, the drug development pipeline is relatively bereft of new strategies. Consequently, there is an urgent and unmet need for developing new strategies and targets for treating osteoporosis. Casual observation led us to hypothesize that much of the bone remodeling research literature focused on relatively few molecular pathways. This led us to perform bibliometric analyses to determine the relative popularity of bone remodeling pathways in publications and US National Institutes of Health funding of the last 10 years. In this review article, we discuss these findings and highlight several less-examined signaling pathways that may hold promise for future therapies.
Appendix
Available only for authorised users
Literature
1.
2.
Leboime A, Confavreux CB, Mehsen N, Paccou J, David C, Roux C. Osteoporosis and mortality. Joint Bone Spine. 2010;77(Suppl 2):S107–12.CrossRefPubMed
3.
Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014;9(1):182.CrossRefPubMed
4.
5.
Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90(1):53–62.CrossRefPubMed
6.
Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22(Suppl 4):1–42.CrossRefPubMed
7.
Watts NB, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl 3):1–37.CrossRefPubMedPubMedCentral
8.
Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford). 2014;53(1):19–31.CrossRef
9.
10.
Qaseem A, Forciea MA, McLean RM, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39.CrossRefPubMed
11.
Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407–13.CrossRefPubMed
12.
Bill Berkrot BH. Heart safety clouds hopes for Amgen, UCB bone drug approval. 2017.
13.
14.
Martineau C, Najyb O, Signor C, Rassart É, Moreau R. Apolipoprotein D deficiency is associated to high bone turnover, low bone mass and impaired osteoblastic function in aged female mice. Metabolism. 2016;65(9):1247–58.CrossRefPubMedPubMedCentral
15.
Ishii M, Koike C, Igarashi A, Yamanaka K, Pan H, Higashi Y, et al. Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts. Biochem Biophys Res Commun. 2005;332(1):297–303.CrossRefPubMed
16.
Schilling AF, Schinke T, Münch C, Gebauer M, Niemeier A, Priemel M, et al. Increased bone formation in mice lacking apolipoprotein E. J Bone Miner Res. 2005;20(2):274–82.CrossRefPubMed
17.
Beak JY, Kang HS, Kim YS, Jetten AM. Kruppel-like zinc finger protein Glis3 promotes osteoblast differentiation by regulating FGF18 expression. J Bone Miner Res. 2007;22(8):1234–44.CrossRefPubMed
18.
19.
Yu H, Du Y, Zhang X, Sun Y, Li S, Dou Y, et al. The aryl hydrocarbon receptor suppresses osteoblast proliferation and differentiation through the activation of the ERK signaling pathway. Toxicol Appl Pharmacol. 2014;280(3):502–510.CrossRefPubMed
20.
21.
Hsu EL, Sonn K, Kannan A, Bellary S, Yun C, Hashmi S, et al. Dioxin exposure impairs BMP-2-mediated spinal fusion in a rat arthrodesis model. J Bone Joint Surg Am. 2015;97(12):1003–10.CrossRefPubMed
22.
Yun C, Weiner JA, Chun DS, Yun J, Cook RW, Schallmo MS, et al. Mechanistic insight into the effects of Aryl Hydrocarbon Receptor activation on osteogenic differentiation. Bone Rep. 2017;6:51–9.CrossRefPubMedPubMedCentral
23.
Tong Y, Niu M, du Y, Mei W, Cao W, Dou Y, et al. Aryl hydrocarbon receptor suppresses the osteogenesis of mesenchymal stem cells in collagen-induced arthritic mice through the inhibition of beta-catenin. Exp Cell Res. 2017;350(2):349–57.CrossRefPubMed
24.
Kung MH, Yukata K, O’Keefe RJ, Zuscik MJ. Aryl hydrocarbon receptor-mediated impairment of chondrogenesis and fracture healing by cigarette smoke and benzo(a)pyrene. J Cell Physiol. 2012;227(3):1062–70.CrossRefPubMedPubMedCentral
25.
Zhou Y, Jiang R, An L, Wang H, Cheng S, Qiong S, et al. Benzo[a]pyrene impedes self-renewal and differentiation of mesenchymal stem cells and influences fracture healing. Sci Total Environ. 2017;587-588:305–15.CrossRefPubMed
26.
Izawa T, Arakaki R, Mori H, Tsunematsu T, Kudo Y, Tanaka E, et al. The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-Fos signaling axis. J Immunol. 2016;197(12):4639–50.CrossRefPubMedPubMedCentral
27.
Yu H, du Y, Zhang X, Sun Y, Li S, Dou Y, et al. The aryl hydrocarbon receptor suppresses osteoblast proliferation and differentiation through the activation of the ERK signaling pathway. Toxicol Appl Pharmacol. 2014;280(3):502–10.CrossRefPubMed
28.
Lapierre DM, Tanabe N, Pereverzev A, Spencer M, Shugg RPP, Dixon SJ, et al. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival. J Biol Chem. 2010;285(33):25792–801.CrossRefPubMedPubMedCentral
29.
Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, Yokoyama W, et al. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum. 2013;65(8):2037–47.CrossRefPubMed
30.
Hwang YS, Ma GT, Park KK, Chung WY. Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling. J Bone Miner Metab. 2014;32(2):110–22.CrossRefPubMed
31.
Chen Z, Luo Q, Lin C, Kuang D, Song G. Simulated microgravity inhibits osteogenic differentiation of mesenchymal stem cells via depolymerizing F-actin to impede TAZ nuclear translocation. Sci Rep. 2016;6(1):30322.CrossRefPubMedPubMedCentral
32.
Masiello LM, Fotos JS, Galileo DS, Karin NJ. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells. Bone. 2006;39(1):72–82.CrossRefPubMed
33.
Chen Z, Luo Q, Lin C, Song G. Simulated microgravity inhibits osteogenic differentiation of mesenchymal stem cells through down regulating the transcriptional co-activator TAZ. Biochem Biophys Res Commun. 2015;468(1–2):21–6.CrossRefPubMed
34.
Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem. 2010;109(4):794–800.PubMed
35.
Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, Briand-Mésange F, Laurencin D, Rue J, et al. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone. 2011;49(3):395–403.CrossRefPubMedPubMedCentral
36.
Shanmugarajan S, Youssef RF, Pati P, Ries WL, Rao DS, Reddy SV. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity. J Cell Biochem. 2008;104(4):1500–8.CrossRefPubMedPubMedCentral
37.
Shanmugarajan S, Beeson CC, Reddy SV. Osteoclast inhibitory peptide-1 binding to the Fc gammaRIIB inhibits osteoclast differentiation. Endocrinology. 2010;151(9):4389–99.CrossRefPubMedPubMedCentral
38.
Shanmugarajan S, Irie K, Musselwhite C, Key LL Jr, Ries WL, Reddy SV. Transgenic mice with OIP-1/hSca overexpression targeted to the osteoclast lineage develop an osteopetrosis bone phenotype. J Pathol. 2007;213(4):420–8.CrossRefPubMedPubMedCentral
39.
Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A. 2009;106(17):7149–54.CrossRefPubMedPubMedCentral
40.
Elabd C, Basillais A, Beaupied H, Breuil V, Wagner N, Scheideler M, et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells. 2008;26(9):2399–407.CrossRefPubMed
41.
Colaianni G, di Benedetto A, Zhu LL, Tamma R, Li J, Greco G, et al. Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem Biophys Res Commun. 2011;411(3):512–5.CrossRefPubMed
42.
Colaianni G, Sun L, di Benedetto A, Tamma R, Zhu LL, Cao J, et al. Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem. 2012;287(34):29159–67.CrossRefPubMedPubMedCentral
43.
Liu X, Shimono K, Zhu LL, Li J, Peng Y, Imam A, et al. Oxytocin deficiency impairs maternal skeletal remodeling. Biochem Biophys Res Commun. 2009;388(1):161–6.CrossRefPubMed
44.
Laffitte A, Neiers F, Briand L. Functional roles of the sweet taste receptor in oral and extraoral tissues. Curr Opin Clin Nutr Metab Care. 2014;17(4):379–85.CrossRefPubMedPubMedCentral
45.
Eaton MS, Weinstein N, Newby JB, Plattes MM, Foster HE, Arthur JW, et al. Loss of the nutrient sensor TAS1R3 leads to reduced bone resorption. J Physiol Biochem. 2018;74(1):3–8.CrossRefPubMed
46.
Simon BR, Learman BS, Parlee SD, Scheller EL, Mori H, Cawthorn WP, et al. Sweet taste receptor deficient mice have decreased adiposity and increased bone mass. PLoS One. 2014;9(1):e86454.CrossRefPubMedPubMedCentral
47.
48.
Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res. 2013;28(11):2392–9.CrossRefPubMed
49.
Brighton PJ, Szekeres PG, Willars GB. Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev. 2004;56(2):231–48.CrossRefPubMed
50.
Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, et al. Central control of bone remodeling by neuromedin U. Nat Med. 2007;13(10):1234–40.CrossRefPubMed
51.
Rucinski M, Ziolkowska A, Tyczewska M, Szyszka M, Malendowicz LK. Neuromedin U directly stimulates growth of cultured rat calvarial osteoblast-like cells acting via the NMU receptor 2 isoform. Int J Mol Med. 2008;22(3):363–8.PubMed
52.
Ruiz-Heiland G, Zhao Y, Derer A, Braun T, Engelke K, Neumann E, et al. Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Ann Rheum Dis. 2014;73(4):771–9.CrossRefPubMed
53.
Nakamura YS, Hakeda Y, Takakura N, Kameda T, Hamaguchi I, Miyamoto T, et al. Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts. Stem Cells. 1998;16(3):229–38.CrossRefPubMed
54.
Stitt TN, Conn G, Goret M, Lai C, Bruno J, Radzlejewski C, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995;80(4):661–70.CrossRefPubMed
55.
Carroll SH, Wigner NA, Kulkarni N, Johnston-Cox H, Gerstenfeld LC, Ravid K. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem. 2012;287(19):15718–27.CrossRefPubMedPubMedCentral
56.
Costa MA, Barbosa A, Neto E, Sá-e-Sousa A, Freitas R, Neves JM, et al. On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells. J Cell Physiol. 2011;226(5):1353–66.CrossRefPubMed
57.
Evans BA, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, et al. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res. 2006;21(2):228–36.CrossRefPubMed
58.
Gharibi B, Abraham AA, Ham J, Evans BAJ. Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. J Bone Miner Res. 2011;26(9):2112–24.CrossRefPubMed
59.
Kara FM, Chitu V, Sloane J, Axelrod M, Fredholm BB, Stanley ER, et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J. 2010;24(7):2325–33.CrossRefPubMedPubMedCentral
60.
61.
Kara FM, Doty SB, Boskey A, Goldring S, Zaidi M, Fredholm BB, et al. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum. 2010;62(2):534–41.CrossRefPubMedPubMedCentral
62.
Hinton DJ, McGee-Lawrence ME, Lee MR, Kwong HK, Westendorf JJ, Choi DS. Aberrant bone density in aging mice lacking the adenosine transporter ENT1. PLoS One. 2014;9(2):e88818.CrossRefPubMedPubMedCentral
Metadata
Title
Bringing Attention to Lesser-known Bone Remodeling Pathways
Authors
Mehdi Shadmand
Krista Jackson
Cecelia Bender
Stephen Donnelly
Henry Guan
Kirby Tobin
Sydni Yates
Julia Hum
Jonathan W. Lowery
Publication date
01-09-2018
Publisher
Springer US
Published in
Clinical & Translational Metabolism / Issue 3/2018
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-018-9250-3

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits